STOCK TITAN

Sol-Gel Technologies Ltd - SLGL STOCK NEWS

Welcome to our dedicated news page for Sol-Gel Technologies (Ticker: SLGL), a resource for investors and traders seeking the latest updates and insights on Sol-Gel Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sol-Gel Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sol-Gel Technologies's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.86%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.19%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.35%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
none
Sol-Gel Technologies Ltd

Nasdaq:SLGL

SLGL Rankings

SLGL Stock Data

27.30M
7.56M
57.99%
28.59%
0.05%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Israel
7 Golda Meir

About SLGL

sol-gel is a clinical-stage specialty pharmaceutical company focused on developing and commercializing topical dermatological drug products. our lead product candidates, vered for the treatment of papulopustular rosacea and twin and sirs-t for the treatment of acne vulgaris (“acne”) are based upon our proprietary microencapsulation delivery system. this technology consists of microcapsules made of silica. based on our pre-clinical and clinical data, this delivery system should enable us to develop and commercialize dermatological drug products that are more effective and/or have fewer side effects than currently marketed drugs. our silica-based delivery system improves the tolerability of topical dermatological drug products by entrapping drug substances in porous silica microcapsules. this creates a protective barrier between the drug substance and the skin and controls the release rate of the drug substance. our delivery system also enables to produce novel fixed-dose combinations th